Hepatic haemangiomas are benign lesions, not even true tumours, and are malformations of blood vessels. Hemangiomas are rarely malignant, most are stable and most require only regular follow-up to observe changes in their condition if there are no clinical symptoms.
In only very rare cases, hepatic haemangiomas may develop adverse outcomes such as rupture and bleeding, or coagulation dysfunction. Therefore, regular follow-up to observe changes in the tumour and close attention to tumour-related symptoms (e.g. abdominal pain, bloating, indigestion, etc.) and symptoms related to coagulation abnormalities (e.g. skin petechiae, etc.) in life are needed to minimise these adverse outcomes.